IRB Advisor – September 1, 2016
September 1, 2016
View Issues
-
New Draft Recommendations and Checklist for Written Policies
Two leading federal agencies in human research have issued draft recommendations and a user-friendly checklist to help IRBs cope with the paperwork avalanche.
-
How Can Teaching Dull Regulations Evolve into Excitement and Real Learning?
People working in human research need to be well-educated about IRBs and federal regulations, but how well are the classes really working if learners appear glassy-eyed and confused?
-
ReguBingo Sample is Focused on Conflicts of Interest
The Southern California Kaiser Permanente IRB of Pasadena has created ReguBingo, a new game for IRBs to use to teach IRB members, staff, researchers and research staff, and others about human research protection regulations.
-
Pre-review Process Can Result in Satisfied Research Staff
A research institution has found that a model way to improve collaboration between research protection staff and research staff is through a study initiation program.
-
Educating IRB Members in 10 Hours or More
A common challenge for IRBs is educating board members who come from a variety of backgrounds and levels of experience.
-
Governor Signs Off on State Law Requiring Oversight of UM Psych Drug Research
Culminating a turbulent saga that began with the suicide of a research subject more than a decade ago, Minnesota Gov. Mark Dayton has signed into law a bill that gives the state unprecedented control and oversight of psychiatric drug research at the University of Minnesota.
-
Report: Socioeconomic Factors Undercut Participation in Internet Studies
Launched by the federal government last year, the Precision Medicine Initiative is a disease prevention and treatment model that is envisioned as linking access to genetic information with the expanding reach of the internet to form research “cohorts” of racially and socially diverse subjects.
-
Another Call for Transparency in Clinical Trials
The demand for clinical trial transparency and research results continues to gain momentum, as it was recently reported that almost half of the data from randomized clinical trials from four sponsors registered at ClinicalTrials.gov were not available to researchers.